ABL Diagnostics (XPAR:ABLD) Cash And Cash Equivalents : €1.54 Mil (As of Jun. 2023)

View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics Cash And Cash Equivalents?

ABL Diagnostics's quarterly cash and cash equivalents declined from Jun. 2022 (€2.53 Mil) to Dec. 2022 (€1.01 Mil) but then increased from Dec. 2022 (€1.01 Mil) to Jun. 2023 (€1.54 Mil).

ABL Diagnostics's annual cash and cash equivalents increased from Dec. 2020 (€2.36 Mil) to Dec. 2021 (€2.70 Mil) but then declined from Dec. 2021 (€2.70 Mil) to Dec. 2022 (€1.01 Mil).

ABL Diagnostics Cash And Cash Equivalents Historical Data

The historical data trend for ABL Diagnostics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics Cash And Cash Equivalents Chart

ABL Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

7.25

6.97

2.36

2.70

1.01

ABL Diagnostics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.72	2.70	2.53	1.01	1.54

ABL Diagnostics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

ABL Diagnostics (XPAR:ABLD) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

ABL Diagnostics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Diagnostics (XPAR:ABLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

72c, rue de, WOIPPY, Thionville, FRA, 57140

Website

https://www.abldiagnostics.com

ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics (XPAR:ABLD) Headlines

No Headlines